The path to gender-affirming care in Australia demands patience, parental agreement, and often years of waiting. For a teenager like Kyro who wanted to start treatment at 16, those requirements can feel like an impossible barrier.
Young people in Australia need a medical diagnosis of gender dysphoria—psychological distress when a person's gender identity does not align with their sex assigned at birth—to receive this care. This diagnosis is only granted after an exhaustive and often onerous medical assessment. Once diagnosed, hormone therapies involving oestrogen and testosterone are only prescribed in Australia once a young person has been deemed capable of giving informed consent, usually around the age of 16. For puberty blockers, parents can consent at a younger age.
The waiting for approval is only one hurdle. Accessing medications through public hospital systems can be difficult, with lengthy waiting lists stretching out for 2-3 years or more. At Monash Health in Victoria, the wait has grown so long that clinics booking appointments in March 2026 were seeing referrals from as far back as November 2023. Geography compounds the problem: those outside major cities struggle to find trained clinicians, and puberty-blocking medications are not available under the PBS (Pharmaceutical Benefits Scheme), with costs proving prohibitively high for some families.
The situation grew more precarious this year. In January 2025, Queensland Health issued a directive preventing no new public patients under 18 years from being prescribed puberty blockers or gender-affirming hormones treatment for gender dysphoria. The state government cited concerns about oversight, particularly following reports of treatments provided to minors without adequate authorisation. Queensland already had its own review of gender-affirming care in 2024. That 104-page report found that care was being delivered safely and effectively and made 25 key recommendations, including increasing investment and expanding access to care.
Yet Queensland took the opposite direction. The pause has disrupted care for young people already in treatment and closed the door to new patients. At least 491 trans young people in Queensland have had their medical care stripped away by a political decision.
The evidence supporting gender-affirming care is substantial. An independent review into gender-affirming care for minors commissioned by the New South Wales government and released in September 2024 found that puberty blockers are 'safe, effective and reversible'. However, they also called for more long-term research. The Royal Australasian College of Physicians, the Royal Australian College of General Practitioners, the Australian Endocrine Society, and AusPATH all support access to puberty blockers for transgender youth. Research indicates real benefits: a 2022 study in JAMA Network Open confirmed that trans youth who receive gender-affirming care experience lower levels of depression and anxiety compared to those who are denied treatment.
Questions of institutional accountability matter here. Queensland justified its pause after reports that gender-affirming hormones had been given to minors as young as 12 years of age without authorised care in the state's far north. If genuine oversight failures occurred, they deserve investigation. But the remedy has proven blunt: freezing access across the entire state rather than addressing specific failures. Federal Health Minister Mark Butler asked Queensland's health minister Tim Nicholls to abide by national standards, saying he did not think the Queensland government's plan to conduct a state-based review was appropriate.
The federal government has announced a review by the National Health and Medical Research Council, with guidelines on the use of puberty blockers to be completed by mid-2026. That process follows established medical guideline development, not a political inquiry.
What becomes clear in this story is a genuine tension between two legitimate concerns. Young people deserve access to evidence-supported medical treatment, and administrators rightly worry about proper oversight and safeguards. Where those things clash, the cost falls hardest on teenagers facing dysphoria and their families trying to navigate a fragmented system already strained by waiting lists and geographic barriers. Queensland's pause may address some governance questions, but it has also blocked care for young people whose cases were already approved and proceeding. That is a real harm, even if the original impulse to investigate came from a genuine place.